{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:41:55Z","timestamp":1793148115918,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID \/ NEU \/ 04539\/2019"],"award-info":[{"award-number":["UID \/ NEU \/ 04539\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/148653\/2019"],"award-info":[{"award-number":["SFRH\/BD\/148653\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.phrs.2020.105325","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T12:01:21Z","timestamp":1606910481000},"page":"105325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Inflammation in Bipolar Disorder (BD): Identification of new therapeutic targets"],"prefix":"10.1016","volume":"163","author":[{"given":"Ana Catarina","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia M.F.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105325_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar Spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0010","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1038\/nrdp.2018.8","article-title":"Bipolar disorders","volume":"4","author":"Vieta","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2020.105325_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jad.2018.10.106","article-title":"Correlation of proinflammatory cytokines levels and reduced gray matter volumes between patients with bipolar disorder and unipolar depression","volume":"245","author":"Chen","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14656566.2018.1426746","article-title":"An overview of pharmacotherapy for bipolar I disorder","volume":"19","author":"Morsel","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2020.105325_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jad.2016.06.063","article-title":"Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: a systematic review","volume":"205","author":"Cullen","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072143","article-title":"A history of the pharmacological treatment of bipolar disorder","volume":"19","author":"L\u00f3pez-Mu\u00f1oz","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1515\/hsz-2015-0257","article-title":"Kinins and microglial responses in bipolar disorder: a neuroinflammation hypothesis","volume":"397","author":"Naaldijk","year":"2016","journal-title":"Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105325_bib0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.12740\/PP\/89553","article-title":"Morphological changes of the brain in mood disorders","volume":"52","author":"Wilczy\u0144ska","year":"2018","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.phrs.2020.105325_bib0045","series-title":"A Historical Dictionary of Psychiatry","author":"Shorter","year":"2005"},{"key":"10.1016\/j.phrs.2020.105325_bib0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/09540260902962198","article-title":"Hyperintense MRI lesions in bipolar disorder: a meta-analysis and review","volume":"21","author":"Beyer","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1399-5618.2012.01000.x","article-title":"Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies","volume":"14","author":"Selvaraj","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11920-014-0541-1","article-title":"Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites","volume":"17","author":"Anderson","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.phrs.2020.105325_bib0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12929-018-0473-x","article-title":"DISC1, and GSK3 complex in mental disorders and therapeutic interventions","volume":"25","author":"Weng","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0070","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(18)32548-0","article-title":"Bipolar disorder","volume":"392","author":"Barnett","year":"2018","journal-title":"Lancet (Lond. Engl.)"},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2020.105325_bib0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/bdi.12700","article-title":"Modelling mood disorders: an ACE solution?","volume":"20","author":"Malhi","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2020.105325_bib0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0090","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7110144","article-title":"Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications","volume":"7","author":"Rosenblat","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0095","doi-asserted-by":"crossref","first-page":"S04","DOI":"10.21035\/ijcnmh.2017.4(Suppl.3).S04","article-title":"The ups and downs of cellular stress: the \u201cMAM hypothesis\u201d for Bipolar disorder pathophysiology","author":"Pereira","year":"2017","journal-title":"Int. J. Clin. Neurosci. Ment. Heal."},{"key":"10.1016\/j.phrs.2020.105325_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165752","article-title":"Mitochondria, endoplasmic reticulum and innate immune dysfunction in mood disorders: do Mitochondria-Associated Membranes (MAMs) play a role?","volume":"1866","author":"Resende","year":"2020","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.phrs.2020.105325_bib0105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0306-9877(81)90044-X","article-title":"A biochemical basis for the actions of lithium on behaviour and on immunity: relapsing and remitting disorders of inflammation and immunity such as multiple sclerosis or recurrent herpes as manic-depression of the immune system","volume":"7","author":"Horrobin","year":"1981","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.phrs.2020.105325_bib0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.psc.2015.09.006","article-title":"Bipolar disorder and inflammation","volume":"39","author":"Rosenblat","year":"2016","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.phrs.2020.105325_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2016.12.059","article-title":"Medical comorbidity in bipolar disorder: the link with metabolic-inflammatory systems","volume":"211","author":"SayuriYamagata","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tibs.2016.10.009","article-title":"Stressed and inflamed, can GSK3 be blamed?","volume":"42","author":"Jope","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0125","doi-asserted-by":"crossref","first-page":"14841","DOI":"10.1074\/jbc.M513737200","article-title":"Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2","volume":"281","author":"Salazar","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105325_bib0130","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/MCB.01204-10","article-title":"SCF\/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner","volume":"31","author":"Rada","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2020.105325_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/986075","article-title":"Elevation of HO-1 expression mitigates intestinal ischemia-reperfusion injury and restores tight junction function in a rat liver transplantation model","volume":"2015","author":"Chi","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2020.105325_bib0140","article-title":"Nrf2 signaling pathway: pivotal roles in inflammation","volume":"1863","author":"SM","year":"2017","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"10.1016\/j.phrs.2020.105325_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2013.12.041","article-title":"Arylbenzofuran isolated from Dalbergia odorifera suppresses lipopolysaccharide-induced mouse BV2 microglial cell activation, which protects mouse hippocampal HT22 cells death from neuroinflammation-mediated toxicity","volume":"728","author":"Lee","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105325_bib0150","doi-asserted-by":"crossref","first-page":"11624","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.105325_bib0155","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/glia.20947","article-title":"Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson\u2019s disease","volume":"58","author":"Rojo","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.phrs.2020.105325_bib0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/ars.2015.6615","article-title":"Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming","volume":"26","author":"Liu","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2020.105325_bib0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcp.2016.05.002","article-title":"Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation","volume":"112","author":"Liu","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105325_bib0170","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.freeradbiomed.2011.05.016","article-title":"Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation","volume":"51","author":"Tsai","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2020.105325_bib0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0180","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00406-017-0848-0","article-title":"Keap1-Nrf2 signaling pathway confers resilience versus susceptibility to inescapable electric stress","volume":"268","author":"Zhang","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2020.105325_bib0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuroscience.2013.10.036","article-title":"Chronic treatment with the mood-stabilizing drug lithium up-regulates nuclear factor E2-related factor 2 in rat pheochromocytoma PC12 cells in vitro","volume":"256","author":"Rizak","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2020.105325_bib0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/1566524016666160126144440","article-title":"The comorbidity of bipolar disorder and migraine: the role of inflammation and oxidative and nitrosative stress","volume":"16","author":"da Costa","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.phrs.2020.105325_bib0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/S1516-44462008000300011","article-title":"Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes","volume":"30","author":"Kapczinski","year":"2008","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.phrs.2020.105325_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nbd.2016.03.009","article-title":"Consequences of brain-derived neurotrophic factor withdrawal in CNS neurons and implications in disease","volume":"97","author":"Mariga","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2020.105325_bib0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/ars.2009.2668","article-title":"Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities","volume":"12","author":"Adibhatla","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2020.105325_bib0210","first-page":"136","article-title":"The underlying neurobiology of bipolar disorder","volume":"2","author":"Manji","year":"2003","journal-title":"World Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0215","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2147\/NDT.S109835","article-title":"Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode","volume":"12","author":"Kurita","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.phrs.2020.105325_bib0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pnpbp.2016.09.004","article-title":"Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology","volume":"72","author":"Data-Franco","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0225","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fpsyt.2018.00767","article-title":"Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies","volume":"9","author":"Li","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0230","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/sj.npp.1300952","article-title":"Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics","volume":"31","author":"Marx","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2020.105325_bib0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.mp.4001888","article-title":"n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism","volume":"12","author":"Rao","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0240","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/mp.2008.31","article-title":"Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?","volume":"13","author":"Rao","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0245","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0006-8993(97)00773-7","article-title":"Inferior collicular seizure generalization produces site-selective cortical induction of cyclooxygenase 2 (COX-2)","volume":"767","author":"McCown","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2020.105325_bib0250","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1073\/pnas.93.6.2317","article-title":"COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex","volume":"93","author":"Kaufmann","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.105325_bib0255","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1749-6632.1989.tb22609.x","article-title":"The role of arachidonic acid and its metabolites in the release of neuropeptides","volume":"559","author":"Ojeda","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0260","first-page":"203","article-title":"The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems","volume":"28","author":"Carabotti","year":"2015","journal-title":"Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105325_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291709005558","article-title":"Not fade away: the HPA axis and depression","volume":"40","author":"Cowen","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.phrs.2020.105325_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/nrn3346","article-title":"Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour","author":"Cryan","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2020.105325_bib0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.31887\/DCNS.2017.19.1\/rmcintyre","article-title":"Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders","volume":"19","author":"Subramaniapillai","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.phrs.2020.105325_bib0280","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s11920-015-0606-9","article-title":"Chronobiology of bipolar disorder: therapeutic implication","volume":"17","author":"Dallaspezia","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.phrs.2020.105325_bib0285","series-title":"Immune System Effects on the Endocrine System","author":"Tsoli","year":"2019"},{"key":"10.1016\/j.phrs.2020.105325_bib0290","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40266-018-0579-6","article-title":"A review of the pharmacological and clinical profile of newer atypical antipsychotics as treatments for bipolar disorder: considerations for use in older patients","volume":"35","author":"Vasudev","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.phrs.2020.105325_bib0295","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jad.2017.12.026","article-title":"Lithium, stress, and resilience in bipolar disorder: deciphering this key homeostatic synaptic plasticity regulator","volume":"233","author":"Machado-Vieira","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0300","unstructured":"B.T. Baune, Inflammation and immunity in depression: basic science and clinical applications, n.d."},{"key":"10.1016\/j.phrs.2020.105325_bib0305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejphar.2008.01.019","article-title":"Olanzapine inhibits glycogen synthase kinase-3\u03b2: an investigation by docking simulation and experimental validation","volume":"584","author":"Mohammad","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105325_bib0310","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.biopsych.2005.10.021","article-title":"Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder","volume":"59","author":"Zarate","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122679","article-title":"An oldie but goodie: lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms","volume":"18","author":"Won","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105325_bib0320","article-title":"GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine","volume":"38","author":"RJ","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2020.105325_bib0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2004.11.022","article-title":"Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T\/C SNP","volume":"376","author":"Benedetti","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2020.105325_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3030547","article-title":"Gsk3 signalling and redox status in bipolar disorder: evidence from Lithium efficacy","volume":"2016","author":"Luca","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2020.105325_bib0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/17460441.2018.1428554","article-title":"Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician\u2019s perspective","volume":"13","author":"Fornaro","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2020.105325_bib0340","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1007\/s00213-019-5175-x","article-title":"Targeting the immune system in the treatment of bipolar disorder","volume":"236","author":"Rosenblat","year":"2019","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.phrs.2020.105325_bib0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","article-title":"Inflamed moods: a review of the interactions between inflammation and mood disorders","volume":"53","author":"Rosenblat","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0350","first-page":"164","article-title":"In the realm of psychoneuroimmunology: the role of celecoxib as an add-on treatment for bipolar mania","volume":"4","author":"Al-Alawi","year":"2018","journal-title":"Mol. Neuropsychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1871527317666181105162347","article-title":"Efficacy of celecoxib adjunct treatment on bipolar disorder: systematic review and meta-analysis","volume":"18","author":"Bavaresco","year":"2019","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.phrs.2020.105325_bib0360","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14737175.2018.1407242","article-title":"Immune-based strategies for mood disorders: facts and challenges","volume":"18","author":"Colpo","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2020.105325_bib0365","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jad.2011.06.005","article-title":"The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial","volume":"135","author":"Berk","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0370","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0004867413481631","article-title":"A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania","volume":"47","author":"da S. Magalh\u00e3es","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0375","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0380","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond","year":"2014","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.phrs.2020.105325_bib0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4306\/pi.2013.10.4.421","article-title":"A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life","volume":"10","author":"Strzelecki","year":"2013","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.phrs.2020.105325_bib0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0395","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11064-006-9233-5","article-title":"Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder","volume":"32","author":"Richardson","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.phrs.2020.105325_bib0400","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12035-010-8131-7","article-title":"DHA metabolism: targeting the brain and lipoxygenation","volume":"42","author":"Picq","year":"2010","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2020.105325_bib0405","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/mp.2015.22","article-title":"Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study","volume":"21","author":"Rapaport","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2020.105325_bib0410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.phrs.2020.105325_bib0415","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bdi.12324","article-title":"Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Arabzadeh","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2020.105325_bib0420","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/cap.2016.0207","article-title":"Double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania","volume":"27","author":"Mousavi","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2020.105325_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2018.02.004","article-title":"Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment","volume":"102","author":"Edberg","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2020.105325_bib0430","unstructured":"Clinical Trial on Bipolar Disorder: N-acetyl cysteine (NAC) - Clinical Trials Registry - ICH GCP, (n.d.). https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03730064 (Accessed October 2, 2020)."},{"key":"10.1016\/j.phrs.2020.105325_bib0435","unstructured":"Clinical Trial on Bipolar Depression: Probiotic Supplement, Inert Compound - Clinical Trials Registry - ICH GCP, (n.d.). https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03349528 (Accessed October 3, 2020)."},{"key":"10.1016\/j.phrs.2020.105325_bib0440","unstructured":"Depression, Obesity and Inflammatory Markers - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02765100 (Accessed October 3, 2020)."},{"key":"10.1016\/j.phrs.2020.105325_bib0445","unstructured":"Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I\/II Depression | Stanford Health Care, (n.d.). https:\/\/stanfordhealthcare.org\/trials\/1\/NCT02363738.html (Accessed October 3, 2020)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:42:01Z","timestamp":1778794921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820316339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":89,"alternative-id":["S1043661820316339"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105325","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation in Bipolar Disorder (BD): Identification of new therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105325"}}